

Raffaele De Caterina

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7964955/publications.pdf>

Version: 2024-02-01

320
papers

43,204
citations

12330

69
h-index

2178

202
g-index

335
all docs

335
docs citations

335
times ranked

37677
citing authors

#	ARTICLE	IF	CITATIONS
1	2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. European Heart Journal, 2016, 37, 2893-2962.	2.2	5,689
2	Guidelines for the management of atrial fibrillation: The Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). European Heart Journal, 2010, 31, 2369-2429.	2.2	4,635
3	2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Europace, 2016, 18, 1609-1678.	1.7	3,523
4	2012 focused update of the ESC Guidelines for the management of atrial fibrillation. European Heart Journal, 2012, 33, 2719-2747.	2.2	3,144
5	Universal Definition of Myocardial Infarction. Circulation, 2007, 116, 2634-2653.	1.6	2,755
6	Fourth universal definition of myocardial infarction (2018). European Heart Journal, 2019, 40, 237-269.	2.2	2,687
7	2012 focused update of the ESC Guidelines for the management of atrial fibrillation. Europace, 2012, 14, 1385-1413.	1.7	2,319
8	Apixaban with Antiplatelet Therapy after Acute Coronary Syndrome. New England Journal of Medicine, 2011, 365, 699-708.	27.0	918
9	Advanced glycation end products and vascular inflammation: implications for accelerated atherosclerosis in diabetes. Cardiovascular Research, 2004, 63, 582-592.	3.8	779
10	2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. European Journal of Cardio-thoracic Surgery, 2016, 50, e1-e88.	1.4	754
11	Olive Oil and Red Wine Antioxidant Polyphenols Inhibit Endothelial Activation. Arteriosclerosis, Thrombosis, and Vascular Biology, 2003, 23, 622-629.	2.4	586
12	nâ€“3 Fatty Acids in Cardiovascular Disease. New England Journal of Medicine, 2011, 364, 2439-2450.	27.0	508
13	Advanced Glycation End Products Activate Endothelium Through Signal-Transduction Receptor RAGE. Circulation, 2002, 105, 816-822.	1.6	501
14	Recommendations for the management of patients after heart valve surgery. European Heart Journal, 2005, 26, 2463-2471.	2.2	488
15	Management of atrial fibrillation in seven European countries after the publication of the 2010 ESC Guidelines on atrial fibrillation: primary results of the PREvention of thromboembolic eventsâ€”European Registry in Atrial Fibrillation (PREFER in AF). Europace, 2014, 16, 6-14.	1.7	349
16	Vitamin K antagonists in heart disease: Current status and perspectives (Section III). Thrombosis and Haemostasis, 2013, 110, 1087-1107.	3.4	347
17	Stroke prevention in atrial fibrillation: Past, present and future. Thrombosis and Haemostasis, 2017, 117, 1230-1239.	3.4	346
18	Bleeding in acute coronary syndromes and percutaneous coronary interventions: position paper by the Working Group on Thrombosis of the European Society of Cardiology. European Heart Journal, 2011, 32, 1854-1864.	2.2	343

#	ARTICLE	IF	CITATIONS
19	Orthostatic Hypotension. <i>Journal of the American College of Cardiology</i> , 2015, 66, 848-860.	2.8	333
20	Major Bleeding in Patients With Atrial Fibrillation Receiving Apixaban or Warfarin. <i>Journal of the American College of Cardiology</i> , 2014, 63, 2141-2147.	2.8	308
21	Efficacy and safety of apixaban compared with warfarin according to age for stroke prevention in atrial fibrillation: observations from the ARISTOTLE trial. <i>European Heart Journal</i> , 2014, 35, 1864-1872.	2.2	303
22	Mediterranean diet polyphenols reduce inflammatory angiogenesis through MMP-9 and COX-2 inhibition in human vascular endothelial cells: A potentially protective mechanism in atherosclerotic vascular disease and cancer. <i>Archives of Biochemistry and Biophysics</i> , 2012, 527, 81-89.	3.0	275
23	New Oral Anticoagulants in Atrial Fibrillation and Acute Coronary Syndromes. <i>Journal of the American College of Cardiology</i> , 2012, 59, 1413-1425.	2.8	257
24	Awake Systolic Blood Pressure Variability Correlates With Target-Organ Damage in Hypertensive Subjects. <i>Hypertension</i> , 2007, 50, 325-332.	2.7	251
25	Soluble Vascular Cell Adhesion Molecule-1 as a Biohumoral Correlate of Atherosclerosis. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 1997, 17, 2646-2654.	2.4	243
26	Growth Differentiation Factor 15, a Marker of Oxidative Stress and Inflammation, for Risk Assessment in Patients With Atrial Fibrillation. <i>Circulation</i> , 2014, 130, 1847-1858.	1.6	243
27	Cardiovascular morbidity and mortality related to orthostatic hypotension: a meta-analysis of prospective observational studies. <i>European Heart Journal</i> , 2015, 36, 1609-1617.	2.2	238
28	Oleic Acid Inhibits Endothelial Activation. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 1999, 19, 220-228.	2.4	210
29	Endothelial permeability, LDL deposition, and cardiovascular risk factors—a review. <i>Cardiovascular Research</i> , 2018, 114, 35-52.	3.8	208
30	Antiplatelet agents for the treatment and prevention of atherothrombosis. <i>European Heart Journal</i> , 2011, 32, 2922-2932.	2.2	203
31	Efficacy and Safety of Apixaban Compared With Warfarin at Different Levels of Predicted International Normalized Ratio Control for Stroke Prevention in Atrial Fibrillation. <i>Circulation</i> , 2013, 127, 2166-2176.	1.6	196
32	At Least 2 Distinct Pathways Generating Reactive Oxygen Species Mediate Vascular Cell Adhesion Molecule-1 Induction by Advanced Glycation End Products. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2005, 25, 1401-1407.	2.4	192
33	Long-term cardiovascular safety of febuxostat compared with allopurinol in patients with gout (FAST): a multicentre, prospective, randomised, open-label, non-inferiority trial. <i>Lancet, The</i> , 2020, 396, 1745-1757.	13.7	192
34	Antithrombotic therapy in the elderly: expert position paper of the European Society of Cardiology Working Group on Thrombosis. <i>European Heart Journal</i> , 2015, 36, ehv304.	2.2	175
35	Estrogens and Glucocorticoids Inhibit Endothelial Vascular Cell Adhesion Molecule-1 Expression by Different Transcriptional Mechanisms. <i>Circulation Research</i> , 2000, 87, 19-25.	4.5	171
36	General mechanisms of coagulation and targets of anticoagulants (Section I). <i>Thrombosis and Haemostasis</i> , 2013, 109, 569-579.	3.4	165

#	ARTICLE	IF	CITATIONS
37	From Asthma to Atherosclerosis – 5-Lipoxygenase, Leukotrienes, and Inflammation. <i>New England Journal of Medicine</i> , 2004, 350, 4-7.	27.0	158
38	Parenteral anticoagulants in heart disease: Current status and perspectives (Section II). <i>Thrombosis and Haemostasis</i> , 2013, 109, 769-786.	3.4	154
39	Aspirin Therapy in Primary Cardiovascular Disease Prevention. <i>Journal of the American College of Cardiology</i> , 2014, 64, 319-327.	2.8	150
40	Non-vitamin K antagonist oral anticoagulants (NOACs): No longer new or novel. <i>Thrombosis and Haemostasis</i> , 2014, 112, 781-782.	3.4	142
41	Adipose Tissue-Derived Stem Cells. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2009, 29, 1723-1729.	2.4	141
42	Thromboembolic Risk, Bleeding Outcomes and Effect of Different Antithrombotic Strategies in Very Elderly Patients With Atrial Fibrillation: A Subanalysis From the PREFER in AF (Prevention of Thromboembolism in Very Elderly Patients With Atrial Fibrillation) Trial. <i>Journal of the American College of Cardiology</i> , 2017, 69, 187-197.	3.7	137
43	Cellular and molecular mechanisms of vascular injury in diabetes – Part I: Pathways of vascular disease in diabetes. <i>Vascular Pharmacology</i> , 2011, 54, 68-74.	2.1	136
44	Edoxaban for the Prevention of Thromboembolism in Patients With Atrial Fibrillation and Bioprosthetic Valves. <i>Circulation</i> , 2017, 135, 1273-1275.	1.6	133
45	The first 3500 years of aspirin history from its roots – A concise summary. <i>Vascular Pharmacology</i> , 2019, 113, 1-8.	2.1	132
46	Control of endothelial leukocyte adhesion molecules by fatty acids. <i>Lipids</i> , 1996, 31, S57-S63.	1.7	129
47	Anticoagulants in heart disease: current status and perspectives. <i>European Heart Journal</i> , 2007, 28, 880-913.	2.2	119
48	Net Clinical Benefit of Adding Clopidogrel to Aspirin Therapy in Patients With Atrial Fibrillation for Whom Vitamin K Antagonists Are Unsuitable. <i>Annals of Internal Medicine</i> , 2011, 155, 579.	3.9	119
49	Low-Density Lipoprotein Level Reduction by the 3-Hydroxy-3-Methylglutaryl Coenzyme-A Inhibitor Simvastatin Is Accompanied by a Related Reduction of F ₂ -Isoprostane Formation in Hypercholesterolemic Subjects. <i>Circulation</i> , 2002, 106, 2543-2549.	1.6	114
50	Hydroxytyrosol suppresses MMP-9 and COX-2 activity and expression in activated human monocytes via PKC α and PKC β 1 inhibition. <i>Atherosclerosis</i> , 2014, 232, 17-24.	0.8	113
51	Nutritional mechanisms that influence cardiovascular disease. <i>American Journal of Clinical Nutrition</i> , 2006, 83, 421S-426S.	4.7	111
52	Diabetic microangiopathy: Pathogenetic insights and novel therapeutic approaches. <i>Vascular Pharmacology</i> , 2017, 90, 1-7.	2.1	111
53	n-3 Fatty Acids in the Treatment of Diabetic Patients. <i>Diabetes Care</i> , 2007, 30, 1012-1026.	8.6	110
54	Homocysteine induces VCAM-1 gene expression through NF- κ B and NAD(P)H oxidase activation: protective role of Mediterranean diet polyphenolic antioxidants. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 2007, 293, H2344-H2354.	3.2	106

#	ARTICLE	IF	CITATIONS
55	Determinants of long-term clinical outcomes in patients with angina but without obstructive coronary artery disease: a systematic review and meta-analysis. <i>European Heart Journal</i> , 2018, 39, 2135-2146.	2.2	105
56	Gender differences in clinical presentation and 1-year outcomes in atrial fibrillation. <i>Heart</i> , 2017, 103, 1024-1030.	2.9	104
57	Non-“Vitamin K Antagonist Oral Anticoagulants in Patients With Atrial Fibrillation and Valvular Heart Disease. <i>Journal of the American College of Cardiology</i> , 2017, 69, 1363-1371.	2.8	102
58	Distal embolization during primary angioplasty: Histopathologic features and predictability. <i>American Heart Journal</i> , 2005, 150, 102-108.	2.7	97
59	Differences among western European countries in anticoagulation management of atrial fibrillation. <i>Thrombosis and Haemostasis</i> , 2014, 112, 833-841.	3.4	96
60	Antioxidant and Anti-Inflammatory Properties of <i>Nigella sativa</i> Oil in Human Pre-Adipocytes. <i>Antioxidants</i> , 2019, 8, 51.	5.1	96
61	Vasculoprotective potential of olive oil components. <i>Molecular Nutrition and Food Research</i> , 2007, 51, 1225-1234.	3.3	90
62	Nutraceuticals and Prevention of Atherosclerosis: Focus on “ Polyunsaturated Fatty Acids and Mediterranean Diet Polyphenols. <i>Cardiovascular Therapeutics</i> , 2010, 28, e13-9.	2.5	89
63	Cholesterol-Lowering Interventions and Stroke. <i>Journal of the American College of Cardiology</i> , 2010, 55, 198-211.	2.8	88
64	Angina Pectoris and Myocardial Ischemia in the Absence of “Obstructive Coronary “Artery “Disease: Practical Considerations for “Diagnostic “Tests. <i>JACC: Cardiovascular Interventions</i> , 2014, 7, 453-463.	2.9	88
65	Simvastatin Attenuates Expression of Cytokine-inducible Nitric-oxide Synthase in Embryonic Cardiac Myoblasts. <i>Journal of Biological Chemistry</i> , 2005, 280, 13503-13511.	3.4	80
66	The dynamics of the coronary collateral circulation. <i>Nature Reviews Cardiology</i> , 2014, 11, 191-197.	13.7	80
67	Coronary Artery Anomalies. <i>Circulation</i> , 2021, 144, 983-996.	1.6	77
68	Awake Blood Pressure Variability, Inflammatory Markers and Target Organ Damage in Newly Diagnosed Hypertension. <i>Hypertension Research</i> , 2008, 31, 2137-2146.	2.7	75
69	Clq/TNF-related protein-1: an adipokine marking and promoting atherosclerosis. <i>European Heart Journal</i> , 2016, 37, 1762-1771.	2.2	75
70	Late Thrombosis After Double Versus Single Drug-Eluting Stent in the Treatment of “Coronary Bifurcations. <i>JACC: Cardiovascular Interventions</i> , 2013, 6, 687-695.	2.9	74
71	Quenching of Intracellular ROS Generation as a Mechanism for Oleate-Induced Reduction of Endothelial Activation and Early Atherogenesis. <i>Thrombosis and Haemostasis</i> , 2002, 88, 335-344.	3.4	73
72	Prevention of atherothrombotic events in patients with diabetes mellitus: from antithrombotic therapies to new-generation glucose-lowering drugs. <i>Nature Reviews Cardiology</i> , 2019, 16, 113-130.	13.7	73

#	ARTICLE	IF	CITATIONS
73	Increased glycated albumin and decreased esRAGE levels are related to angiographic severity and extent of coronary artery disease in patients with type 2 diabetes. <i>Atherosclerosis</i> , 2009, 206, 540-545.	0.8	69
74	Prognostically relevant periprocedural myocardial injury and infarction associated with percutaneous coronary interventions: a Consensus Document of the ESC Working Group on Cellular Biology of the Heart and European Association of Percutaneous Cardiovascular Interventions (EAPCI). <i>European Heart Journal</i> , 2021, 42, 2630-2642.	2.2	69
75	High glucose-induced hyperosmolarity contributes to COX-2 expression and angiogenesis: implications for diabetic retinopathy. <i>Cardiovascular Diabetology</i> , 2016, 15, 18.	6.8	67
76	Insulin-Requiring Versus Noninsulin-Requiring Diabetes and Thromboembolic Risk in Patients With Atrial Fibrillation. <i>Journal of the American College of Cardiology</i> , 2017, 69, 409-419.	2.8	67
77	Increased serum high-mobility group box-1 and cleaved receptor for advanced glycation endproducts levels and decreased endogenous secretory receptor for advanced glycation endproducts levels in diabetic and non-diabetic patients with heart failure. <i>European Journal of Heart Failure</i> , 2011, 13, 440-449.	7.1	65
78	The Extra-Virgin Olive Oil Polyphenols Oleocanthal and Oleacein Counteract Inflammation-Related Gene and miRNA Expression in Adipocytes by Attenuating NF- κ B Activation. <i>Nutrients</i> , 2019, 11, 2855.	4.1	63
79	Rapid Decline of Collateral Circulation Increases Susceptibility to Myocardial Ischemia. <i>Journal of the American College of Cardiology</i> , 2006, 48, 59-65.	2.8	62
80	Long-term Use of Anti-inflammatory Drugs and Risk of Atrial Fibrillation. <i>Archives of Internal Medicine</i> , 2010, 170, 1450-5.	3.8	62
81	Antiarrhythmic effects of omega-3 fatty acids: from epidemiology to bedside. <i>American Heart Journal</i> , 2003, 146, 420-430.	2.7	61
82	The JAK-STAT pathway: an emerging target for cardiovascular disease in rheumatoid arthritis and myeloproliferative neoplasms. <i>European Heart Journal</i> , 2021, 42, 4389-4400.	2.2	61
83	Complete myocardial revascularization confers a larger clinical benefit when performed with state-of-the-art techniques in high-risk patients with multivessel coronary artery disease: A meta-analysis of randomized and observational studies. <i>Catheterization and Cardiovascular Interventions</i> , 2016, 87, 3-12.	1.7	60
84	Effects of omega-3 fatty acids on cytokines and adhesion molecules. <i>Current Atherosclerosis Reports</i> , 2004, 6, 485-491.	4.8	55
85	Glycaemic control in acute coronary syndromes: prognostic value and therapeutic options. <i>European Heart Journal</i> , 2010, 31, 1557-1564.	2.2	54
86	Genetic determinants of blood pressure responses to caffeine drinking. <i>American Journal of Clinical Nutrition</i> , 2012, 95, 241-248.	4.7	54
87	Transplantation of adipose tissue mesenchymal cells conjugated with VEGF-releasing microcarriers promotes repair in murine myocardial infarction. <i>Cardiovascular Research</i> , 2015, 108, 39-49.	3.8	54
88	Cellular and molecular mechanisms of vascular injury in diabetes – Part II: Cellular mechanisms and therapeutic targets. <i>Vascular Pharmacology</i> , 2011, 54, 75-79.	2.1	53
89	The left atrial appendage: from embryology to prevention of thromboembolism. <i>European Heart Journal</i> , 2017, 38, ehw159.	2.2	53
90	Cardioversion of Atrial Fibrillation in ENGAGE AF-TIMI 48. <i>Clinical Cardiology</i> , 2016, 39, 345-346.	1.8	53

#	ARTICLE	IF	CITATIONS
91	Extra virgin olive oil rich in polyphenols modulates VEGF-induced angiogenic responses by preventing NADPH oxidase activity and expression. <i>Journal of Nutritional Biochemistry</i> , 2016, 28, 19-29.	4.2	53
92	Additive Regulation of Adiponectin Expression by the Mediterranean Diet Olive Oil Components Oleic Acid and Hydroxytyrosol in Human Adipocytes. <i>PLoS ONE</i> , 2015, 10, e0128218.	2.5	51
93	The non-vitamin K antagonist oral anticoagulants (NOACs) and extremes of body weight—a systematic literature review. <i>Clinical Research in Cardiology</i> , 2017, 106, 565-572.	3.3	50
94	Risk factors for thromboembolic and bleeding events in anticoagulated patients with atrial fibrillation: the prospective, multicentre observational PREvention of thromboembolic events - European Registry in Atrial Fibrillation (PREFER in AF). <i>BMJ Open</i> , 2019, 9, e022478.	1.9	50
95	n-3 fatty acids: Antiatherosclerotic effects. <i>Lipids</i> , 2001, 36, S69-S78.	1.7	49
96	Circulating endothelial progenitor cells: Do they live up to their name?. <i>Vascular Pharmacology</i> , 2015, 67-69, 2-5.	2.1	49
97	Impact of Sex Differences and Diabetes on Coronary Atherosclerosis and Ischemic Heart Disease. <i>Journal of Clinical Medicine</i> , 2019, 8, 98.	2.4	49
98	Net Clinical Benefit of Non-Vitamin K Antagonist vs Vitamin K Antagonist Anticoagulants in Elderly Patients with Atrial Fibrillation. <i>American Journal of Medicine</i> , 2019, 132, 749-757.e5.	1.5	48
99	Strong association of the APOA5-1131T>C gene variant and early-onset acute myocardial infarction. <i>Atherosclerosis</i> , 2011, 214, 397-403.	0.8	47
100	Diabetic macroangiopathy: Pathogenetic insights and novel therapeutic approaches with focus on high glucose-mediated vascular damage. <i>Vascular Pharmacology</i> , 2018, 107, 27-34.	2.1	47
101	Innate and adaptive immunity in atherosclerosis. <i>Vascular Pharmacology</i> , 2018, 107, 67-77.	2.1	46
102	Endothelial dysfunctions: common denominators in vascular disease. <i>Current Opinion in Clinical Nutrition and Metabolic Care</i> , 2000, 3, 453-467.	2.5	45
103	PCSK9 and atherosclerosis: Looking beyond LDL regulation. <i>European Journal of Clinical Investigation</i> , 2021, 51, e13459.	3.4	45
104	The epicardial adipose tissue and the coronary arteries: dangerous liaisons. <i>Cardiovascular Research</i> , 2019, 115, 1013-1025.	3.8	44
105	Therapeutic potential of the dual peroxisome proliferator activated receptor (PPAR) α/β agonist aleglitazar in attenuating TNF α -mediated inflammation and insulin resistance in human adipocytes. <i>Pharmacological Research</i> , 2016, 107, 125-136.	7.1	43
106	Inflammation and thrombosis — testing the hypothesis with anti-inflammatory drug trials. <i>Thrombosis and Haemostasis</i> , 2016, 116, 1012-1021.	3.4	42
107	Relevance of new drug discovery to reduce NF- κ B activation in cardiovascular disease. <i>Vascular Pharmacology</i> , 2012, 57, 41-47.	2.1	41
108	Non-vitamin K antagonist oral anticoagulants in atrial fibrillation accompanying mitral stenosis: the concept for a trial. <i>Europace</i> , 2016, 18, 6-11.	1.7	38

#	ARTICLE	IF	CITATIONS
109	Heart failure subtypes and thromboembolic risk in patients with atrial fibrillation: The PREFER in AF - HF substudy. <i>International Journal of Cardiology</i> , 2018, 265, 141-147.	1.7	38
110	Prognostic Role of Late Gadolinium Enhancement in Patients With Hypertrophic Cardiomyopathy and Low-to-Intermediate Sudden Cardiac Death Risk Score. <i>American Journal of Cardiology</i> , 2019, 124, 1286-1292.	1.6	38
111	Hydroxytyrosol Modulates Adipocyte Gene and miRNA Expression Under Inflammatory Condition. <i>Nutrients</i> , 2019, 11, 2493.	4.1	38
112	Efficacy and safety of edoxaban in patients early after surgical bioprosthetic valve implantation or valve repair: A randomized clinical trial. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2023, 165, 58-67.e4.	0.8	38
113	Prolonged exposure to high insulin impairs the endothelial PI3-kinase/Akt/nitric oxide signalling. <i>Thrombosis and Haemostasis</i> , 2009, 101, 345-350.	3.4	37
114	Mechanical prosthetic heart valves: Quality of anticoagulation and thromboembolic risk. The observational multicenter PLECTRUM study. <i>International Journal of Cardiology</i> , 2018, 267, 68-73.	1.7	36
115	Mortality predictors and effects of antithrombotic therapies in atrial fibrillation: insights from ACTIVE-W. <i>European Heart Journal</i> , 2010, 31, 2133-2140.	2.2	35
116	Antithrombotic Therapy in Patients Undergoing Transcatheter Interventions for Structural Heart Disease. <i>Circulation</i> , 2021, 144, 1323-1343.	1.6	35
117	Effects of Olive Oil on Blood Pressure: Epidemiological, Clinical, and Mechanistic Evidence. <i>Nutrients</i> , 2020, 12, 1548.	4.1	34
118	Both vitamin B6 and total homocysteine plasma levels predict long-term atherothrombotic events in healthy subjects. <i>European Heart Journal</i> , 2007, 28, 484-491.	2.2	33
119	Heart failure due to right ventricular apical pacing: the importance of flow patterns. <i>Europace</i> , 2016, 18, 1679-1688.	1.7	33
120	Association of PCSK9 plasma levels with metabolic patterns and coronary atherosclerosis in patients with stable angina. <i>Cardiovascular Diabetology</i> , 2019, 18, 144.	6.8	33
121	Mid-term outcomes after percutaneous interventions in coronary bifurcations. <i>International Journal of Cardiology</i> , 2019, 283, 78-83.	1.7	33
122	Edoxaban for stroke prevention in atrial fibrillation in routine clinical care: 1-year follow-up of the prospective observational ETNA-AF-Europe study. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2021, 7, f30-f39.	3.0	33
123	Selective inhibition of thromboxane-related platelet function by low-dose aspirin in patients after myocardial infarction. <i>American Journal of Cardiology</i> , 1985, 55, 589-590.	1.6	32
124	Net Clinical Benefit of Non-vitamin K Antagonist Oral Anticoagulants Versus Warfarin in Phase III Atrial Fibrillation Trials. <i>American Journal of Medicine</i> , 2015, 128, 1007-1014.e2.	1.5	32
125	High glucose-induced hyperosmolarity impacts proliferation, cytoskeleton remodeling and migration of human induced pluripotent stem cells via aquaporin-1. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2014, 1842, 2266-2275.	3.8	31
126	Short-term prevention of thromboembolic complications in patients with atrial fibrillation with aspirin plus clopidogrel: the Clopidogrel-Aspirin Atrial Fibrillation (CLAAF) Pilot Study. <i>American Heart Journal</i> , 2004, 148, 180.	2.7	30

#	ARTICLE	IF	CITATIONS
127	Insulin potentiates cytokine-induced VCAM-1 expression in human endothelial cells. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2008, 1782, 511-516.	3.8	30
128	Non-Vitamin K Antagonist Oral Anticoagulants for Mechanical Heart Valves. <i>Circulation</i> , 2018, 138, 1356-1365.	1.6	30
129	Imaging of the vulnerable carotid plaque. <i>Neurology</i> , 2020, 94, 922-932.	1.1	30
130	Characteristics of patients initiated on edoxaban in Europe: baseline data from edoxaban treatment in routine clinical practice for patients with atrial fibrillation (AF) in Europe (ETNA-AF-Europe). <i>BMC Cardiovascular Disorders</i> , 2019, 19, 165.	1.7	29
131	Elevated glycated albumin and reduced endogenous secretory receptor for advanced glycation endproducts levels in serum predict major adverse cardio-cerebral events in patients with type 2 diabetes and stable coronary artery disease. <i>International Journal of Cardiology</i> , 2015, 197, 241-247.	1.7	28
132	Prognostic Role of Cardiac Magnetic Resonance in Arrhythmogenic Right Ventricular Cardiomyopathy. <i>American Journal of Cardiology</i> , 2018, 122, 1745-1753.	1.6	28
133	The Non-Vitamin K Antagonist Oral Anticoagulants in Heart Disease: Section V Special Situations. <i>Thrombosis and Haemostasis</i> , 2019, 119, 014-038.	3.4	28
134	Clinical and Pharmacological Effects of Apixaban Dose Adjustment in the ARISTOTLE Trial. <i>Journal of the American College of Cardiology</i> , 2020, 75, 1145-1155.	2.8	28
135	¹¹¹ In Platelet Scintigraphy for the Noninvasive Detection of Carotid Plaque Thrombosis. <i>Stroke</i> , 2001, 32, 719-727.	2.0	27
136	Frequent and possibly inappropriate use of combination therapy with an oral anticoagulant and antiplatelet agents in patients with atrial fibrillation in Europe. <i>Heart</i> , 2014, 100, 1625-1635.	2.9	27
137	Genetic determinants of cognitive responses to caffeine drinking identified from a double-blind, randomized, controlled trial. <i>European Neuropsychopharmacology</i> , 2015, 25, 798-807.	0.7	27
138	Ranolazine in the prevention of anthracycline cardiotoxicity. <i>Pharmacological Research</i> , 2014, 79, 88-102.	7.1	26
139	Involvement of the TP receptor in TNF- α -induced endothelial tissue factor expression. <i>Vascular Pharmacology</i> , 2014, 62, 49-56.	2.1	26
140	COVID-19-related cardiac complications from clinical evidences to basic mechanisms: opinion paper of the ESC Working Group on Cellular Biology of the Heart. <i>Cardiovascular Research</i> , 2021, 117, 2148-2160.	3.8	26
141	Effect of High-Dose Atorvastatin Reload on the Release of Endothelial Progenitor Cells in Patients on Long-Term Statin Treatment Who Underwent Percutaneous Coronary Intervention (from the TjETQq1 1 0.784314.rgBT /Overdock 10 T		
142	CHA ₂ DS ₂ -VASc score and adverse outcomes in middle-aged individuals without atrial fibrillation. <i>European Journal of Preventive Cardiology</i> , 2019, 26, 1987-1997.	1.8	25
143	Oral anticoagulants in coronary heart disease (Section IV) Position paper of the ESC Working Group on Thrombosis - Task Force on Anticoagulants in Heart Disease. <i>Thrombosis and Haemostasis</i> , 2016, 115, 685-711.	3.4	24
144	Outcomes of anticoagulated patients with atrial fibrillation treated with or without antiplatelet therapy - A pooled analysis from the PREFER in AF and PREFER in AF PROLONGATON registries. <i>International Journal of Cardiology</i> , 2018, 270, 160-166.	1.7	24

#	ARTICLE	IF	CITATIONS
145	Oxidative stress and vascular stiffness in hypertension: A renewed interest for antioxidant therapies?. <i>Vascular Pharmacology</i> , 2019, 116, 45-50.	2.1	24
146	Design and rationale of the Edoxaban Treatment in routine clinical practice for patients with Atrial Fibrillation in Europe (ETNA-AF-Europe) study. <i>Journal of Cardiovascular Medicine</i> , 2019, 20, 97-104.	1.5	24
147	Patients With Atrial Fibrillation Taking Nonsteroidal Anti-Inflammatory Drugs and Oral Anticoagulants in the ARISTOTLE Trial. <i>Circulation</i> , 2020, 141, 10-20.	1.6	24
148	Empagliflozin reduces the senescence of cardiac stromal cells and improves cardiac function in a murine model of diabetes. <i>Journal of Cellular and Molecular Medicine</i> , 2020, 24, 12331-12340.	3.6	24
149	Isolated troponin increase after percutaneous coronary interventions: Does it have prognostic relevance?. <i>Atherosclerosis</i> , 2012, 221, 297-302.	0.8	23
150	Aterogénesis y diabetes: resistencia a la insulina e hiperinsulinemia. <i>Revista Espanola De Cardiologia</i> , 2012, 65, 309-313.	1.2	23
151	The new oral anticoagulants in atrial fibrillation: Once daily or twice daily?. <i>Vascular Pharmacology</i> , 2013, 59, 53-62.	2.1	23
152	Co-Activation of Nuclear Factor- κ B and Myocardin/Serum Response Factor Conveys the Hypertrophy Signal of High Insulin Levels in Cardiac Myoblasts. <i>Journal of Biological Chemistry</i> , 2014, 289, 19585-19598.	3.4	23
153	Thrombotic and hemorrhagic burden in women: Gender-related issues in the response to antithrombotic therapies. <i>International Journal of Cardiology</i> , 2019, 286, 198-207.	1.7	23
154	Platelet Indices and Risk of Death and Cardiovascular Events: Results from a Large Population-Based Cohort Study. <i>Thrombosis and Haemostasis</i> , 2019, 119, 1773-1784.	3.4	22
155	Pharmacological modulation of vascular inflammation in atherothrombosis. <i>Annals of the New York Academy of Sciences</i> , 2010, 1207, 23-31.	3.8	21
156	Quality of life and patient satisfaction in patients with atrial fibrillation on stable vitamin K antagonist treatment or switched to a non-vitamin K antagonist oral anticoagulant during a 1-year follow-up: A PREFER in AF Registry substudy. <i>Archives of Cardiovascular Diseases</i> , 2018, 111, 74-84.	1.6	21
157	Nutrients and Gene Expression. , 2004, 93, 99-133.		20
158	Pathways and Drugs in Pulmonary Arterial Hypertension – Focus on the Role of Endothelin Receptor Antagonists. <i>Cardiovascular Drugs and Therapy</i> , 2015, 29, 469-479.	2.6	20
159	Stroke Prevention in Atrial Fibrillation: Current Status and Near-Future Directions. <i>American Journal of Medicine</i> , 2011, 124, 793-799.	1.5	19
160	Glucose Metabolism, Hyperosmotic Stress, and Reprogramming of Somatic Cells. <i>Molecular Biotechnology</i> , 2013, 55, 169-178.	2.4	19
161	Role and importance of ultrasound lung comets in acute cardiac care. <i>European Heart Journal: Acute Cardiovascular Care</i> , 2015, 4, 103-112.	1.0	19
162	Quenching of intracellular ROS generation as a mechanism for oleate-induced reduction of endothelial activation and early atherogenesis. <i>Thrombosis and Haemostasis</i> , 2002, 88, 335-44.	3.4	19

#	ARTICLE	IF	CITATIONS
163	Stroke Prevention in Atrial Fibrillation: A Clinical Perspective on Trials of the Novel Oral Anticoagulants. <i>Cardiovascular Drugs and Therapy</i> , 2016, 30, 201-214.	2.6	18
164	Cholesterol-lowering interventions and stroke: Insights from IMPROVE-IT. <i>Atherosclerosis</i> , 2016, 248, 216-218.	0.8	18
165	The safety and efficacy of non-vitamin K antagonist oral anticoagulants in atrial fibrillation in the elderly. <i>International Journal of Cardiology</i> , 2018, 265, 118-124.	1.7	18
166	The current role of anticoagulants in cardiovascular medicine. <i>Journal of Cardiovascular Medicine</i> , 2009, 10, 595-604.	1.5	17
167	Transplantation of Mesenchymal Cells Improves Peripheral Limb Ischemia in Diabetic Rats. <i>Molecular Biotechnology</i> , 2014, 56, 438-448.	2.4	17
168	Non-Vitamin K Antagonist Oral Anticoagulants for Cardioversion in Atrial Fibrillation: An Updated Meta-analysis. <i>American Journal of Medicine</i> , 2017, 130, 457-461.	1.5	17
169	Proteomic analysis of the secretome of adipose tissue-derived murine mesenchymal cells overexpressing telomerase and myocardin. <i>Journal of Molecular and Cellular Cardiology</i> , 2019, 131, 171-186.	1.9	17
170	From short-term blood pressure variability to atherosclerosis: Relative roles of vascular stiffness and endothelial dysfunction. <i>Journal of Clinical Hypertension</i> , 2020, 22, 1218-1227.	2.0	17
171	Pre-treatment high-sensitivity troponin T for the short-term prediction of cardiac outcomes in patients on immune checkpoint inhibitors. <i>European Journal of Clinical Investigation</i> , 2021, 51, e13400.	3.4	17
172	Three-dimensional echographic evaluation of carotid artery disease. <i>Journal of Cardiovascular Echography</i> , 2018, 28, 218.	0.4	17
173	History of bleeding and outcomes with apixaban versus warfarin in patients with atrial fibrillation in the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation trial. <i>American Heart Journal</i> , 2016, 175, 175-183.	2.7	16
174	Oral anticoagulant use in octogenarian European patients with atrial fibrillation: A subanalysis of PREFER in AF. <i>International Journal of Cardiology</i> , 2017, 232, 98-104.	1.7	16
175	Grading of aortic stenosis severity: a head-to-head comparison between cardiac magnetic resonance imaging and echocardiography. <i>Radiologia Medica</i> , 2018, 123, 643-654.	7.7	16
176	The global Edoxaban Treatment in routine clinical practice (ETNA) noninterventional study program: rationale and design. <i>Clinical Cardiology</i> , 2019, 42, 1147-1154.	1.8	16
177	Ponatinib Induces Vascular Toxicity through the Notch-1 Signaling Pathway. <i>Journal of Clinical Medicine</i> , 2020, 9, 820.	2.4	16
178	Perceived vs. objective frailty in patients with atrial fibrillation and impact on anticoagulant dosing: an ETNA-AF-Europe sub-analysis. <i>Europace</i> , 2022, 24, 1404-1411.	1.7	16
179	Omega-3 fatty acids, atherogenesis, and endothelial activation. <i>Journal of Cardiovascular Medicine</i> , 2007, 8, S11-S14.	1.5	15
180	Nitrates and Other Nitric Oxide Donors in Cardiology - Current Positioning and Perspectives. <i>Cardiovascular Drugs and Therapy</i> , 2012, 26, 55-69.	2.6	15

#	ARTICLE	IF	CITATIONS
181	Determinants of left atrium thrombi in scheduled cardioversion: an ENSURE-AF study analysis. <i>Europace</i> , 2019, 21, 1633-1638.	1.7	15
182	Mortality Prediction of the CHA2DS2-VASc Score, the HAS-BLED Score, and Their Combination in Anticoagulated Patients with Atrial Fibrillation. <i>Journal of Clinical Medicine</i> , 2020, 9, 3987.	2.4	15
183	Simulated hyperglycemia impairs insulin signaling in endothelial cells through a hyperosmolar mechanism. <i>Vascular Pharmacology</i> , 2020, 130, 106678.	2.1	15
184	Aquaporin-1 and Sodium-Hydrogen Exchangers as Pharmacological Targets in Diabetic Atherosclerosis. <i>Current Drug Targets</i> , 2015, 16, 361-365.	2.1	15
185	Bivalirudin for acute coronary syndromes: premises, promises and doubts. <i>Thrombosis and Haemostasis</i> , 2015, 113, 698-707.	3.4	14
186	Efficacy and Safety of Non-Vitamin K Antagonist Oral Anticoagulants After Cardioversion for Nonvalvular Atrial Fibrillation. <i>American Journal of Medicine</i> , 2016, 129, 1117-1123.e2.	1.5	14
187	Cholesterol Lowering and Stroke: No Longer Room for Pleiotropic Effects of Statins â€œ Confirmation from PCSK9 Inhibitor Studies. <i>American Journal of Medicine</i> , 2020, 133, 95-99.e6.	1.5	14
188	Safety and Effectiveness of Edoxaban in Atrial Fibrillation Patients in Routine Clinical Practice: One-Year Follow-Up from the Global Noninterventional ETNA-AF Program. <i>Journal of Clinical Medicine</i> , 2021, 10, 573.	2.4	14
189	Atherogenesis and Diabetes: Focus on Insulin Resistance and Hyperinsulinemia. <i>Revista Espanola De Cardiologia (English Ed)</i> , 2012, 65, 309-313.	0.6	13
190	Proton pump inhibitors and clopidogrel: an association to avoid?. <i>Internal and Emergency Medicine</i> , 2014, 9, 11-22.	2.0	13
191	Cell based mechanosensing in vascular patho-biology: More than a simple go-with the flow. <i>Vascular Pharmacology</i> , 2018, 111, 7-14.	2.1	13
192	Transplantation of telomerase/myocardin-co-expressing mesenchymal cells in the mouse promotes myocardial revascularization and tissue repair. <i>Vascular Pharmacology</i> , 2020, 135, 106807.	2.1	13
193	Transcriptome-based identification of new anti-inflammatory and vasodilating properties of the n-3 fatty acid docosahexaenoic acid in vascular endothelial cell under proinflammatory conditions. <i>PLoS ONE</i> , 2015, 10, e0129652.	2.5	13
194	Sodium-glucose cotransporter type 2 inhibitors prevent ponatinib-induced endothelial senescence and dysfunction: A potential rescue strategy. <i>Vascular Pharmacology</i> , 2022, 142, 106949.	2.1	13
195	Clinical Use of Aspirin in Ischemic Heart Disease: Past, Present and Future. <i>Current Pharmaceutical Design</i> , 2012, 18, 5215-5223.	1.9	12
196	Connexin 43 and Connexin 26 Involvement in the Ponatinib-Induced Cardiomyopathy: Sex-Related Differences in a Murine Model. <i>International Journal of Molecular Sciences</i> , 2021, 22, 5815.	4.1	12
197	Sodiumâ€œhydrogen exchangers (NHE) in human cardiovascular diseases: Interfering strategies and their therapeutic applications. <i>Vascular Pharmacology</i> , 2013, 59, 127-130.	2.1	11
198	Is Complete Revascularisation Mandated for all Patients with Multivessel Coronary Artery Disease?. <i>Interventional Cardiology Review</i> , 2017, 13, 45.	1.6	11

#	ARTICLE	IF	CITATIONS
199	Thromboembolic and bleeding risk in obese patients with atrial fibrillation according to different anticoagulation strategies. <i>International Journal of Cardiology</i> , 2020, 318, 67-73.	1.7	11
200	Reclassification, Thromboembolic, and Major Bleeding Outcomes Using Different Estimates of Renal Function in Anticoagulated Patients With Atrial Fibrillation: Insights From the PREFER-in-AF and PREFER-in-AF Prolongation Registries. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2021, 14, e006852.	2.2	11
201	Aspirin for primary cardiovascular prevention: advice for a decisional strategy still based on risk stratification. <i>Anatolian Journal of Cardiology</i> , 2019, 23, 70-78.	0.9	11
202	Receiver operating characteristic (ROC) curves and the definition of threshold levels to diagnose coronary artery disease on electrocardiographic stress testing. Part II: The use of ROC curves in the choice of electrocardiographic stress test markers of ischaemia. <i>Journal of Cardiovascular Medicine</i> , 2008, 9, 22-31.	1.5	10
203	Impact of statin therapy intensity on endothelial progenitor cells after percutaneous coronary intervention in diabetic patients. The REMEDY-EPC late study. <i>International Journal of Cardiology</i> , 2017, 244, 112-118.	1.7	10
204	The acute impact of high-dose lipid-lowering treatment on endothelial progenitor cells in patients with coronary artery diseaseâ€”The REMEDY-EPC early substudy. <i>PLoS ONE</i> , 2017, 12, e0172800.	2.5	10
205	The WOEST study: Critical considerations and applicability. <i>Cor Et Vasa</i> , 2014, 56, e254-e258.	0.1	9
206	Non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation and atrial thrombosis: An appraisal of current evidence. <i>Archives of Cardiovascular Diseases</i> , 2020, 113, 642-651.	1.6	9
207	Controversial Relationship Between Renin-Angiotensin System Inhibitors and Severity of COVID-19. <i>Hypertension</i> , 2020, 76, 312-313.	2.7	9
208	Telomerase/myocardin expressing mesenchymal cells induce survival and cardiovascular markers in cardiac stromal cells undergoing ischaemia/reperfusion. <i>Journal of Cellular and Molecular Medicine</i> , 2021, 25, 5381-5390.	3.6	9
209	OUP accepted manuscript. <i>European Heart Journal</i> , 2021, , .	2.2	9
210	Endothelial Progenitor Cells in Coronary Artery Disease: From Bench to Bedside. <i>Stem Cells Translational Medicine</i> , 2022, 11, 451-460.	3.3	9
211	Potential roles of vessel wall heparan sulfate proteoglycans in atherosclerosis. <i>Vascular Pharmacology</i> , 2014, 60, 49-51.	2.1	8
212	Determinants of subacute response to clopidogrel: relative impact of CYP2C19 genotype and PGE1/adenylate cyclase signalling. <i>Thrombosis Research</i> , 2015, 136, 308-314.	1.7	8
213	Targeting thrombin long-term after an acute coronary syndrome: Opportunities and challenges. <i>Vascular Pharmacology</i> , 2016, 81, 1-14.	2.1	8
214	Ultra-Sensitive Copeptin and Cardiac Troponin in Diagnosing Non-ST-Segment Elevation Acute Coronary Syndromesâ€”The COPACS Study. <i>American Journal of Medicine</i> , 2016, 129, 105-114.	1.5	8
215	Edoxaban in Atrial Fibrillation and Venous Thromboembolismâ€”Ten Key Questions and Answers: A Practical Guide. <i>Advances in Therapy</i> , 2017, 34, 620-637.	2.9	8
216	Aspirin and the Primary Prevention of Cardiovascular Diseases: An Approach Based on Individualized, Integrated Estimation of Risk. <i>High Blood Pressure and Cardiovascular Prevention</i> , 2017, 24, 331-339.	2.2	8

#	ARTICLE	IF	CITATIONS
217	Endothelial Dysfunction, Fibrinolytic Activity, and Coagulation Activity in Patients With Atrial Fibrillation According to Type II Diabetes Mellitus Status. <i>American Journal of Cardiology</i> , 2020, 125, 751-758.	1.6	8
218	Growth Differentiation Factor 15 in Severe Aortic Valve Stenosis: Relationship with Left Ventricular Remodeling and Frailty. <i>Journal of Clinical Medicine</i> , 2020, 9, 2998.	2.4	8
219	Isolated Exercise-Induced Pulmonary Hypertension Associates with Higher Cardiovascular Risk in Scleroderma Patients. <i>Journal of Clinical Medicine</i> , 2020, 9, 1910.	2.4	8
220	Should We Continue Assessing Glomerular Filtration Rate with the Cockcroft-Gault Formula in NOAC-Treated Patients? The Magnitude of the Problem. <i>Journal of Clinical Medicine</i> , 2020, 9, 1893.	2.4	8
221	A case report of multisite arterial thrombosis in a patient with coronavirus disease 2019 (COVID-19). <i>European Heart Journal - Case Reports</i> , 2021, 5, ytaa339.	0.6	8
222	Nutrigenomic Effect of Hydroxytyrosol in Vascular Endothelial Cells: A Transcriptomic Profile Analysis. <i>Nutrients</i> , 2021, 13, 3990.	4.1	8
223	Aspirin-triggered lipoxin in patients treated with aspirin and selective nonselective COX-2 inhibitors. <i>British Journal of Clinical Pharmacology</i> , 2010, 69, 303-306.	2.4	7
224	Association of the European Society of Cardiology echocardiographic probability grading for pulmonary hypertension with short and mid-term clinical outcomes after heart valve surgery. <i>Vascular Pharmacology</i> , 2020, 125-126, 106648.	2.1	7
225	Vitamin K antagonists and osteoporotic fractures: insights from comparisons with the NOACs. <i>European Heart Journal</i> , 2020, 41, 1109-1111.	2.2	7
226	Evaluation of the prognostic value of GDF-15, ABC-AF-bleeding score and ABC-AF-death score in patients with atrial fibrillation across different geographical areas. <i>Open Heart</i> , 2021, 8, e001471.	2.3	7
227	Impact of Weight on Clinical Outcomes of Edoxaban Therapy in Atrial Fibrillation Patients Included in the ETNA-AF-Europe Registry. <i>Journal of Clinical Medicine</i> , 2021, 10, 2879.	2.4	7
228	Long-Term Engraftment and Angiogenic Properties of Lentivirally Transduced Adipose Tissue-Derived Stromal Cells. <i>Molecular Biotechnology</i> , 2013, 54, 13-24.	2.4	6
229	ST segment/heart rate hysteresis improves the diagnostic accuracy of ECG stress test for coronary artery disease in patients with left ventricular hypertrophy. <i>European Journal of Preventive Cardiology</i> , 2016, 23, 1632-1639.	1.8	6
230	The <i>European Heart Journal</i> : leading the fight to reduce the global burden of cardiovascular disease. <i>European Heart Journal</i> , 2020, 41, 3113-3116.	2.2	6
231	Commentary: Temporarily omitting oral anticoagulants early after stenting for acute coronary syndromes patients with atrial fibrillation. <i>International Journal of Cardiology</i> , 2020, 318, 82-85.	1.7	6
232	Co-expression of glycosylated aquaporin-1 and transcription factor NFAT5 contributes to aortic stiffness in diabetic and atherosclerosis-prone mice. <i>Journal of Cellular and Molecular Medicine</i> , 2020, 24, 2857-2865.	3.6	6
233	Factors associated with the dosing of edoxaban for stroke prevention in patients with atrial fibrillation from South Korea and Taiwan: 1-year data from the Global ETNA-AF Program. <i>Journal of the Chinese Medical Association</i> , 2021, 84, 485-490.	1.4	6
234	Heterogeneity of diabetes as a risk factor for major adverse cardiovascular events in anticoagulated patients with atrial fibrillation: an analysis of the ARISTOTLE trial. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2022, 8, 227-235.	3.0	6

#	ARTICLE	IF	CITATIONS
235	The Vessels-Bone Axis: Iliac Artery Calcifications, Vertebral Fractures and Vitamin K from VIKI Study. <i>Nutrients</i> , 2021, 13, 3567.	4.1	6
236	Sex-related differential susceptibility to ponatinib cardiotoxicity and differential modulation of the Notch1 signalling pathway in a murine model. <i>Journal of Cellular and Molecular Medicine</i> , 2022, , .	3.6	6
237	Rivaroxaban in mitral stenosis (RISE MS): A pilot randomized clinical trial. <i>International Journal of Cardiology</i> , 2022, 356, 83-86.	1.7	6
238	Rosuvastatin for Reduction of Myocardial Damage during Coronary Angioplasty - the Remedy Trial. <i>Cardiovascular Drugs and Therapy</i> , 2016, 30, 465-472.	2.6	5
239	Von Willebrand factor, ADAMTS13, and coronary microvascular obstruction: beautiful hypotheses, ugly facts. <i>Cardiovascular Research</i> , 2016, 111, 169-171.	3.8	5
240	Relation of Stroke and Bleeding Risk Profiles to Efficacy and Safety of Edoxaban for Cardioversion of Atrial Fibrillation (from the Edoxaban versus warfarin in subjects Undergoing cardioversion) <i>Thrombosis and Haemostasis</i> , 2016, 116, 1000-1007.	1.0	5
241	The co-predictive value of a cardiovascular score for CV outcomes in diabetic patients with no atrial fibrillation. <i>Diabetes/Metabolism Research and Reviews</i> , 2019, 35, e3145.	4.0	5
242	Aspirin Therapy for Primary Prevention: The Case for Continuing Prescribing to Patients at High Cardiovascular Risk—A Review. <i>Thrombosis and Haemostasis</i> , 2020, 120, 199-206.	3.4	5
243	Left Ventricular Size Predicts Clinical Benefit After Percutaneous Mitral Valve Repair for Secondary Mitral Regurgitation: A Systematic Review and Meta-Regression Analysis. <i>Cardiovascular Revascularization Medicine</i> , 2020, 21, 857-864.	0.8	5
244	Optimal Antithrombotic Treatment of Patients with Atrial Fibrillation Early after an Acute Coronary Syndrome—Triple Therapy, Dual Antithrombotic Therapy with an Anticoagulant—Or, Rather, Temporary Dual Antiplatelet Therapy?. <i>Journal of Clinical Medicine</i> , 2020, 9, 2673.	2.4	5
245	Evaluation of the Age, Biomarkers, and Clinical History—Bleeding Risk Score in Patients With Atrial Fibrillation With Combined Aspirin and Anticoagulation Therapy Enrolled in the ARISTOTLE and RE-LY Trials. <i>JAMA Network Open</i> , 2020, 3, e2015943.	5.9	5
246	Benefit of dual antithrombotic therapy with direct oral anticoagulants in patients with atrial fibrillation undergoing percutaneous coronary intervention: a systematic review and metaanalysis of randomized clinical trials. <i>Internal and Emergency Medicine</i> , 2020, 15, 1093-1104.	2.0	5
247	Insulin-treated versus noninsulin-treated diabetes and risk of ischemic stroke in patients with atrial fibrillation. <i>Vascular Pharmacology</i> , 2021, 136, 106809.	2.1	5
248	Lipid-Lowering Therapy in Patients with Coronary Heart Disease and Prior Stroke: Mission Impossible?. <i>Journal of Clinical Medicine</i> , 2021, 10, 886.	2.4	5
249	Many Good Reasons to Switch from Vitamin K Antagonists to Non-Vitamin K Antagonists in Patients with Non-Valvular Atrial Fibrillation. <i>Journal of Clinical Medicine</i> , 2021, 10, 2866.	2.4	5
250	Endothelial Progenitor Cells in Coronary Atherosclerosis and Percutaneous Coronary Intervention: A Systematic Review and Meta-Analysis. <i>Cardiovascular Revascularization Medicine</i> , 2022, 42, 94-99.	0.8	5
251	Clinical Performance of Oral Anticoagulants in Elderly with Atrial Fibrillation and Low Body Weight: Insight into Italian Cohort of PREFER-AF and PREFER-AF Prolongation Registries. <i>Journal of Clinical Medicine</i> , 2022, 11, 3751.	2.4	5
252	New anticoagulants for atrial fibrillation. <i>Journal of Cardiovascular Medicine</i> , 2009, 10, 446-453.	1.5	4

#	ARTICLE	IF	CITATIONS
253	Opportunities and Challenges in Nutrigenetics/Nutrigenomics and Health. <i>Journal of Nutrigenetics and Nutrigenomics</i> , 2010, 3, 137-143.	1.3	4
254	Cancer after intense and prolonged antiplatelet therapies – fact or fiction?. <i>Thrombosis and Haemostasis</i> , 2015, 114, 1100-1103.	3.4	4
255	Intracardiac thrombi during warfarin anticoagulation - A case report and a brief literature review. <i>Cor Et Vasa</i> , 2017, 59, e277-e281.	0.1	4
256	Where are clots in atrial fibrillation? Did we have the wrong assumptions over the last decades?. <i>Europace</i> , 2020, 22, 845-846.	1.7	4
257	Effect of concomitant antiplatelet agents on clinical outcomes in the edoxaban vs warfarin in subjects undergoing cardioversion of atrial fibrillation (ENSURE-AF) randomized trial. <i>Clinical Research in Cardiology</i> , 2020, 109, 1374-1380.	3.3	4
258	Antithrombotic management and outcomes of patients with atrial fibrillation treated with NOACs early at the time of market introduction: Main results from the PREFER in AF Prolongation Registry. <i>Internal and Emergency Medicine</i> , 2021, 16, 591-599.	2.0	4
259	Is there equivalence between PCI and CABG surgery in long-term survival of patients with diabetes? Importance of interpretation biases and biological plausibility. <i>European Heart Journal</i> , 2021, 43, 68-70.	2.2	4
260	Exercise-induced pulmonary hypertension in HIV patients: Association with poor clinical and immunological status. <i>Vascular Pharmacology</i> , 2021, 139, 106888.	2.1	4
261	Aspirin for primary cardiovascular prevention: why the wonder drug should not be precipitously dismissed. <i>Polish Archives of Internal Medicine</i> , 2020, 130, 121-129.	0.4	4
262	Coffee Bioactive N-Methylpyridinium Attenuates Tumor Necrosis Factor (TNF)- α -Mediated Insulin Resistance and Inflammation in Human Adipocytes. <i>Biomolecules</i> , 2021, 11, 1545.	4.0	4
263	Left Atrial Remodeling and Stroke in Patients With Sinus Rhythm and Normal Ejection Fraction: ARIC-ACS. <i>Journal of the American Heart Association</i> , 2022, 11, e024292.	3.7	4
264	Fraud in biomedical research – The role of journal Editors. <i>Vascular Pharmacology</i> , 2011, 55, 119-120.	2.1	3
265	Aspirin in heart failure: don't throw the baby (aspirin) out with the bathwater. <i>European Journal of Heart Failure</i> , 2017, 19, 1089-1094.	7.1	3
266	Coronary computed tomography angiography, ECG stress test and nuclear imaging as sources of false-positive results in the detection of coronary artery disease. <i>Journal of Cardiovascular Medicine</i> , 2018, 19, e133-e138.	1.5	3
267	Sex Implications in the Response to Anticoagulant Therapy in Atrial Fibrillation. <i>Journal of the American College of Cardiology</i> , 2018, 72, 283-286.	2.8	3
268	Challenges in ischaemic heart disease: not sleeping enough, not brushing your teeth, and skipping breakfast – three ways of increasing your risk of myocardial infarction?. <i>European Heart Journal Supplements</i> , 2020, 22, L57-L60.	0.1	3
269	Clustering of blood cell count abnormalities and future risk of death. <i>European Journal of Clinical Investigation</i> , 2021, 51, e13562.	3.4	3
270	Factors for heterogeneous outcomes of angina and myocardial ischemia without obstructive coronary atherosclerosis. <i>Journal of Internal Medicine</i> , 2022, 291, 197-206.	6.0	3

#	ARTICLE	IF	CITATIONS
271	OUP accepted manuscript. European Heart Journal, 2022, , .	2.2	3
272	Failure in evoking the trigeminal cardiac reflex by mandibular stretching in healthy volunteers. Archives Italiennes De Biologie, 2015, 153, 25-36.	0.4	3
273	Detecting the vulnerable carotid plaque: the Carotid Artery Multimodality imaging Prognostic study design. Journal of Cardiovascular Medicine, 2022, 23, 466-473.	1.5	3
274	Oral anticoagulants for atrial fibrillation and acute coronary syndrome with or without stenting. Journal of Cardiovascular Medicine, 2018, 19, e40-e45.	1.5	2
275	Deficiency of NDUFC2: Cause or bystander in acute coronary syndromes?. International Journal of Cardiology, 2019, 286, 134-135.	1.7	2
276	Antithrombotic treatment strategies after PCI. Lancet, The, 2020, 395, 865.	13.7	2
277	Comparing TEE vs Non-TEE guided cardioversion of atrial fibrillation: The ENSURE-AF trial. European Journal of Clinical Investigation, 2020, 50, e13221.	3.4	2
278	Prevention of contrast-induced nephropathy with urine alkalinization: the TEATE study design. Journal of Cardiovascular Medicine, 2020, 21, 65-72.	1.5	2
279	The nomenclature vagaries for the clinical manifestations of myocardial ischemic syndromes – A call to action. International Journal of Cardiology, 2020, 304, 5-7.	1.7	2
280	Characteristics of patients with atrial fibrillation prescribed edoxaban in Belgium and The Netherlands: insights from the ETNA-AF-Europe study. Acta Cardiologica, 2021, 76, 431-439.	0.9	2
281	Patient Preferences of Low-Dose Aspirin for Cardiovascular Disease and Colorectal Cancer Prevention in Italy: A Latent Class Analysis. Patient, 2021, 14, 661-672.	2.7	2
282	Excessive Orthostatic Changes in Blood Pressure Are Associated With Incident Heart Failure in Older Men. Hypertension, 2021, 77, 1481-1489.	2.7	2
283	Interpreting myocardial infarction analyses in ISCHEMIA: separating facts from fallacy. European Heart Journal, 2021, 42, 2986-2989.	2.2	2
284	Eighty years of oral anticoagulation: Learning from history. Vascular Pharmacology, 2021, 141, 106918.	2.1	2
285	ST-segment/heart rate hysteresis improves the exercise testing accuracy for coronary artery detection in asymptomatic patients with severe aortic stenosis. Journal of Cardiovascular Medicine, 2021, 22, 323-325.	1.5	2
286	Clinical Events with Edoxaban in South Korean and Taiwanese Atrial Fibrillation Patients in Routine Clinical Practice. Journal of Clinical Medicine, 2021, 10, 5337.	2.4	2
287	Association of Circulating Heme Oxygenase-1, Lipid Profile and Coronary Disease Phenotype in Patients with Chronic Coronary Syndrome. Antioxidants, 2021, 10, 2002.	5.1	2
288	Fast vs. ultraslow thrombolytic infusion regimens in patients with obstructive mechanical prosthetic valve thrombosis: a pilot randomized clinical trial. European Heart Journal - Cardiovascular Pharmacotherapy, 2022, 8, 668-676.	3.0	2

#	ARTICLE	IF	CITATIONS
289	Fraud in biomedical research – The role of journal Editors. <i>Life Sciences</i> , 2011, 89, 755-756.	4.3	1
290	Reprint of – Potential roles of vessel wall heparan sulfate proteoglycans in atherosclerosis –. <i>Vascular Pharmacology</i> , 2014, 62, 120-122.	2.1	1
291	The new ACCF/AHA guidelines on the treatment of dyslipidemia: pros. <i>Internal and Emergency Medicine</i> , 2015, 10, 115-117.	2.0	1
292	How safe are non-vitamin K antagonist oral anticoagulants in atrial fibrillation?. <i>European Heart Journal Supplements</i> , 2016, 18, 11-16.	0.1	1
293	All cholesterol-lowering interventions are expected to reduce stroke: Confirmatory data from IMPROVE-IT. <i>Data in Brief</i> , 2016, 7, 1541-1550.	1.0	1
294	Do we need P2Y12 inhibitor pretreatment in non-ST elevation acute coronary syndrome?. <i>Revista Portuguesa De Cardiologia</i> , 2016, 35, 319-321.	0.5	1
295	Scoring atherosclerosis in the search of evidence-based personalized medicine. <i>International Journal of Cardiology</i> , 2018, 261, 30-31.	1.7	1
296	Is there an – atherosclerotic continuum –™ from angina with unobstructed coronary arteries to MINOCA? Reply. <i>European Heart Journal</i> , 2019, 40, 1988-1988.	2.2	1
297	Spontaneous conversion in patients with non-valvular atrial fibrillation planned for electrical cardioversion: A subanalysis of the Edoxaban versus warfarin in subjects Undergoing cardioversion Of Atrial Fibrillation (ENSURE-AF) trial. <i>American Heart Journal</i> , 2019, 209, 131-135.	2.7	1
298	The Nutrigenetics of Cardiovascular Disease. , 2020, , 355-360.		1
299	Comparison of Dabigatran Plus a P2Y12 Inhibitor With Warfarin-Based Triple Therapy Across Body Mass Index in RE-DUAL PCI. <i>American Journal of Medicine</i> , 2020, 133, 1302-1312.	1.5	1
300	Is coronary flow velocity reserve just a marker of a higher atherosclerotic burden?. <i>European Heart Journal</i> , 2021, 42, 1444-1445.	2.2	1
301	Extent and progression of atherosclerosis in carotid and subclavian arteries: the Carotid Artery Subclavian Artery study. <i>Journal of Cardiovascular Medicine</i> , 2021, 22, 652-656.	1.5	1
302	A highly-detailed anatomical study of normal pericardial structures as revealed by in-vivo computed tomography and magnetic resonance images and ex-vivo novel 3D reconstructions from Visible Human Server. <i>Imaging</i> , 2021, 13, 1-12.	0.3	1
303	Bleeding risk score: limits and practicability. <i>Heart</i> , 2022, 108, 246-248.	2.9	1
304	New cardiovascular risk factors: homocysteine and vitamins involved in homocysteine metabolism. <i>Italian Heart Journal: Official Journal of the Italian Federation of Cardiology</i> , 2004, 5 Suppl 6, 19S-24S.	0.1	1
305	Exercise-Induced Pulmonary Hypertension Is Associated with High Cardiovascular Risk in Patients with HIV. <i>Journal of Clinical Medicine</i> , 2022, 11, 2447.	2.4	1
306	Management of pregnant women with artificial heart valves: inconsistency in ESC publications: reply. <i>European Heart Journal</i> , 2007, 28, 2419-2420.	2.2	0

#	ARTICLE	IF	CITATIONS
307	Diabetes research in Vascular Pharmacology – An overview of 2011–2012. Vascular Pharmacology, 2013, 58, 251-252.	2.1	0
308	Do we need P2Y12 inhibitor pretreatment in non-ST elevation acute coronary syndrome?. Revista Portuguesa De Cardiologia (English Edition), 2016, 35, 319-321.	0.2	0
309	Percutaneous coronary interventions for non-ST elevation acute coronary syndromes – The two faces of inappropriateness. International Journal of Cardiology, 2018, 255, 20-21.	1.7	0
310	Why include the humanities in medical studies?. Internal and Emergency Medicine, 2020, 15, 523-524.	2.0	0
311	Antiplatelet therapy in patients with acute coronary syndromes and thrombocytopaenia: awaiting for evidence. European Heart Journal - Case Reports, 2021, 5, ytaa577.	0.6	0
312	COVID-19 cardiological research in France: A nationwide perspective. Archives of Cardiovascular Diseases, 2021, 114, 337-339.	1.6	0
313	Response to –Current evidence and future perspective for the management of left sided prosthetic valve thrombosis–. European Heart Journal - Cardiovascular Pharmacotherapy, 2022, , .	3.0	0
314	Low-dose aspirin in the primary prevention of cardiovascular disease: how to balance the benefits and the risks. Italian Heart Journal: Official Journal of the Italian Federation of Cardiology, 2003, 4, 228-31.	0.1	0
315	A Prospective Study to Evaluate the Effectiveness of Edoxaban for the Resolution of Left Atrial Thrombosis in Patients with Atrial Fibrillation. Journal of Clinical Medicine, 2022, 11, 1945.	2.4	0
316	A Therapeutic Pathway in Patients with Chronic Coronary Syndromes: Proposal for Optimization. Journal of Clinical Medicine, 2022, 11, 2091.	2.4	0
317	531 Neuroimaging assessment of unilateral asymptomatic carotid artery stenosis: preliminary results of the carotid artery multi-modality imaging prognostic (camp) study. European Heart Journal Supplements, 2021, 23, .	0.1	0
318	651 –Prevention of contrast induced nephropathy with urine alkalinization: the final results of the TEATE study. European Heart Journal Supplements, 2021, 23, .	0.1	0
319	The non-vitamin K antagonist oral anticoagulants and heparin-induced prolongation of the activated coagulation time. Vascular Pharmacology, 2022, 144, 106994.	2.1	0
320	Response to –Non-vitamin K antagonist oral anticoagulants (NOACs) in preventing thromboembolism in atrial fibrillation patients with moderate to severe mitral stenosis: Results from a pilot trial–. International Journal of Cardiology, 2022, , .	1.7	0